#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Peritoneal mesothelioma malignant Henoch-Schonlein purpura Cold type haemolytic anaemia Osteosarcoma Noonan syndrome Isodicentric chromosome 15 syndrome Brain injury Glycogen storage disease type I SAPHO syndrome IgA nephropathy Fatty acid oxidation disorder Transferrin decreased Metastatic malignant melanoma Small intestine leiomyosarcoma Oesophageal carcinoma More trials…

    Learn about Rare Diseases

    Pleural mesothelioma malignant – Life with Disease Ocular melanoma Tuberous sclerosis complex – Life with Disease Fabry’s disease – Treatment Myelodysplastic syndrome – Basic Information Isodicentric chromosome 15 syndrome – Basic Information Bronchopulmonary dysplasia – Trials in Disease Mucopolysaccharidosis I – Diagnostics Epidermolysis bullosa – Trials in Disease Fabry’s disease – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Moxifloxacin Hydrochloride Ltp001 Phenazone Betamethasone Acetate NORELGESTROMIN Lufepirsen Vancomycin Hydrochloride Rezpegaldesleukin Lauromacrogol 400 Faricimab BGB-16673 Eteplirsen Avatrombopag Sibeprenlimab Mva-209-Fsp-B3 Anitocabtagene Autoleucel Pentixather Osteodex Pegunigalsidase Alfa Resomelagon More therapies…

    Learn about Your Condition

    Hairy cell leukaemia recurrent Hypereosinophilic syndrome Retinal neovascularisation Hip arthroplasty Hypoparathyroidism Inflammatory bowel disease HER2 protein overexpression Colon cancer stage II Neonatal asphyxia Mitral valve disease Paget's disease of the vulva Meningorrhagia Bladder cancer recurrent Foetal growth restriction Fracture infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effects of Tumor Removal in Patients with Metastatic Kidney Cancer Treated with Nivolumab and Ipilimumab Combination

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic renal cell carcinoma
    Investigated Drugs:
    • Axitinib
    • Cabozantinib
    • Ipilimumab
    Italy

  • Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • 5,8-Dichloro-2-[(4-Methoxy-6-Methyl-2-Oxo-1,2-Dihydropyridin-3-Yl)Methyl]-7-[(R)-Methoxy(Oxetan-3-Yl)Methyl]-3,4-Dihydroisoquinolin-1(2H)-One
    • Enzalutamide
    Bulgaria Czechia Denmark Finland France Germany +8

  • Study on Abatacept for Predicting Treatment Response in Patients with Early Rheumatoid Arthritis

    Recruiting

    3 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Abatacept
    Belgium Italy The Netherlands Portugal Spain

  • Study on the Effectiveness and Safety of Ianalumab for Patients with Diffuse Cutaneous Systemic Sclerosis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Systemic scleroderma
    Investigated Drugs:
    • Entecavir
    • Ianalumab
    • Tenofovir Disoproxil
    Austria Belgium France Germany Greece Hungary +4

  • Study on the Effects of Ensifentrine for Patients with Non-Cystic Fibrosis Bronchiectasis

    Recruiting

    2 1
    Investigated Diseases:
    • Bronchiectasis
    Investigated Drugs:
    • ENSIFENTRINE
    Italy Spain

  • Study of alpha-1 antitrypsin given intravenously to hospitalized patients during COPD exacerbation

    Recruiting

    2 1 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Human Alpha1-Proteinase Inhibitor
    • Sodium Chloride
    Italy

  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease

    Recruiting

    3 1 1
    Investigated Drugs:
    • Vedolizumab
    • Upadacitinib
    Austria Belgium Croatia Czechia Denmark France +12

  • Study on Cisplatin, Nab-paclitaxel, and Nivolumab with Radiotherapy for Patients with Non-Metastatic Muscle Invasive Bladder Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Cisplatin
    • Nivolumab
    • Paclitaxel Albumin-Bound
    Italy

  • Study on Oxygen and Nitrous Oxide Use in Critically Ill Adults on Ventilators

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Nitrous Oxide
    • Oxygen
    Italy

  • Study on Olaparib for Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Olaparib
    Italy
Previous Page
1 … 17 18 19 20 21 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!